OP 1.8 – 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir

OP 1.8 – 00204 Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir

Bibliographic Details
Main Authors:	Y. Kim, C. Tumpach, J. Ong, A. Solomon, J. McMahon, P. Arandjelovic, M. Pelligrini, M. Roche, S. Lewin
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664022000413

Similar Items

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
by: Damjan Avsec, et al.
Published: (2022-10-01)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
by: Anna Richter, et al.
Published: (2021-03-01)

Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin
by: Nasreddine El Omari, et al.
Published: (2023-08-01)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
by: Martijn Kerkhofs, et al.
Published: (2020-07-01)

Romidepsin controls chronic lymphocytic leukemia in a patient with mycosis fungoides
by: David M. Lemchak, et al.
Published: (2016-11-01)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
by: Jorge Rodríguez-Afonso, et al.
Published: (2023-08-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

BCL-2 inhibitor venetoclax-innovating the therapeutic pattern of acute myeloid leukemia
by: WANG Xiaoling, et al.
Published: (2023-08-01)

HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (Study BCN02)
by: Mothe, B, et al.
Published: (2020)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
by: Qiang Cao, et al.
Published: (2023-11-01)

Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
by: Haneen T. Salah, et al.
Published: (2021-06-01)

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth
by: Lilly Velentza, et al.
Published: (2023-05-01)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
by: Ida Vänttinen, et al.
Published: (2023-08-01)

PP 8.9 – 00142 Safety and activity of BCL-2 inhibitor Venetoclax in uninfected rhesus macaques
by: T. Wiche Salinas, et al.
Published: (2022-12-01)

OP 2.5 – 00048 Targeting the SIV reservoir with Alemtuzumab
by: B. Varco-Merth, et al.
Published: (2022-12-01)

AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia
by: Noémie Legrand, et al.
Published: (2021-11-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
by: Paillas, S, et al.
Published: (2020)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
by: M. Kalac, et al.
Published: (2022-06-01)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
by: R. Harrigan, et al.
Published: (2022-06-01)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
by: Xiaoyan Hu, et al.
Published: (2023-02-01)

In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial
by: Rosás-Umbert, M, et al.
Published: (2020)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
by: Christian Mayr, et al.
Published: (2021-07-01)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
by: Vishnupriya Kanakaveti, et al.
Published: (2022-10-01)

Individual and Synergistic Anti-Coronavirus Activities of SOCS1/3 Antagonist and Interferon α1 Peptides
by: Chulbul M. Ahmed, et al.
Published: (2022-06-01)

P615: BCL2 RESISTANCE MUTATIONS IN A REAL-WORLD COHORT OF PATIENTS WITH VENETOCLAX-TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA
by: L. Kotmayer, et al.
Published: (2022-06-01)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
by: Marco V. Haselager, et al.
Published: (2023-06-01)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
by: W. Mo, et al.
Published: (2022-06-01)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
by: Xiaoxian Zhao, et al.
Published: (2020-07-01)

HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients’ T-cells
by: Annika P. Schnell, et al.
Published: (2022-08-01)

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
by: Francine Foss, et al.
Published: (2016-03-01)

Synergistic and antagonistic effects of Zinc Bioaccumulation with lead and antioxidant activities in centella asiatica
by: G.H., Ong, et al.
Published: (2013)

Synergistic and antagonistic effects of zinc bioaccumulation with lead and antioxidant activities in Centella asiatica
by: Ong, Ghim Hock, et al.
Published: (2013)

P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX
by: Simon Renders, et al.
Published: (2023-08-01)

P469: ACUTE MYELOID LEUKEMIA DRIVES BCL-2 UPREGULATION IN NON MALIGNANT HSPCS WHICH IS TARGETED BY VENETOCLAX AND CAUSES CYTOPENIA
by: Dominic Fowler-Shorten, et al.
Published: (2023-08-01)

Reservoir capacity and yield /
by: 430842 McMahon, T. A., et al.
Published: (1978)

River and reservoir yield /
by: 430842 McMahon, T. A., et al.
Published: (1986)

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
by: Loke, J, et al.
Published: (2021)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
by: Ayano Nakamura, et al.
Published: (2021-10-01)

Teaching and research in Malaysian public universities: Synergistic or antagonistic?
by: Norzaini Azman, et al.
Published: (2014)